Christopher Tompkins Ph.D., joined KromaTiD in 2011. He is the President and General Manager and is a member of the Board of Directors. He has twenty years of pharmaceutical and biotechnology industry experience focused in the areas of process development, operations and the commercialization of new technologies. Dr. Tompkins past experience includes COO at Evia Medical, Vice President of Operations and Chief Compliance Officer at Atrius Bioscience, General Manager of Proligo LLC, and other executive roles at Proligo. Dr. Tompkins has also lead projects and performed engineering development for two marketed pharmaceutical products; at NeXstar Pharmaceuticals, he led the development team and designed the reactor technology for the macular degeneration treatment, Macugen™; and at Hoffmann-La Roche he was jointly responsible for the development and scale-up of the 5-FU pro-drug Xeloda™. Dr. Tompkins graduated with a Bachelor of Science degree in Chemical Engineering from the University of Michigan and a Ph.D. in Chemical Engineering from North Carolina State University.
David Sebesta Ph.D., Chief Commercial Officer, joined KromaTiD in 2016. He has twenty three years of pharmaceutical and biotechnology industry experience in the areas of synthetic chemistry; carbohydrate, nucleoside and oligonucleotide chemical process development; multidisciplinary R&D management; the commercialization of new technologies; and CMO-sector sales and business development. He was previously Director, Strategic Accounts, at Catalent Pharma Solutions; CEO of MBC Pharma, Founder and Principal consultant of the Prescient Group LLC; COO of BST, Inc.; and Director, R&D of Proligo LLC. Dr. Sebesta also taught undergraduate- and graduate-level organic chemistry as a Lecturer in the University of Colorado, Department of Chemistry and Biochemistry. Dr. Sebesta has a B.S. in Biochemistry from the University of New Mexico, a Ph.D. in Chemistry from Indiana University and was a NIH Post-doctoral Fellow at the University of Colorado.
Gretchen Pratt, Sr. Director of Operations, has been with KromaTiD since 2014. Prior to joining KromaTiD, Ms. Pratt spent 9 years at Amgen in a variety of roles within Operations, including manufacturing, engineering, project management, and risk management. She has previous roles as Operations Manager at AlloSource, and Sr. Manager Primers & Probes at Proligo. Ms. Pratt has a B.A. in Chemistry from Kalamazoo College, M.S. in Chemical Engineering from the University of Virginia, and is a Certified Lean Six Sigma Green Belt (ASQ).
Erin Robinson, Research Manager at KromaTiD, was the company’s first employee hire in 2009 and has helped envision, develop, and launch KromaTiD technology over the past 7 years. Prior to her work with KromaTiD, Ms. Robinson worked as a molecular biologist at the CDC in the areas of West Nile Virus genetics and mosquito vector biology. She holds a Master of Science in Microbiology, Immunology and Pathology and a B.S. in Biological Science, both from Colorado State University, and serves as a board member of the Northern Colorado Climber’s Coalition.